Analyst: Big Opportunities Coming In Medical Device Space

Medical Device
From The Gold Report: The stage has been set for high levels of uncertainty, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena.
NYSE:XHE February 24, 2017 7:45am

This Biotech ETF Looks Primed To Rally Again

The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016 posting a loss of more than 20%, has started posting gains again and is looking like the rally may be poised to continue.
NASDAQ:IBB February 20, 2017 6:42am

Healthcare Is Bouncing Back, And Medical Devices Are Leading The Way

Medical Device
From Taki Tsaklanos: The health care stock market sector is back in shape. The XLV ETF representing the healthcare sector was up 0.14 percent for the day and 2.2 percent for the week.
NYSE:IHI February 18, 2017 8:43am

A Major Recovery Is Brewing In The Biotech & Healthcare Space

From Taki Tsaklanos: Biotechnology was once the darling of stock market investors. Not so anymore, since the summer of 2015 the sector collapsed from 400 points to 250 points in the IBB ETF.
NASDAQ:IBB February 17, 2017 6:33am

Biotech’s Next Big Catalyst Could Be Synthetic DNA

From Jon Markman: It really is a brave new world. Not long ago, a group of prominent scientists announced plans for a project to create synthetic human DNA from scratch.
NASDAQ:IBB February 14, 2017 9:21am

Biotech ETF Recovery Powered By Big Earnings Improvements

From Zacks: The biotech industry, which was shunned by investors last year, made a strong comeback following Trump’s victory in anticipation of softer regulation.
NASDAQ:IBB February 10, 2017 10:49am

Gilead Sciences, Inc. Is A Weak Stock That Keeps Getting Weaker

From Corey Rosenbloom: “Strong Stocks Keep Getting Stronger while Weak Stocks Keep Getting Weaker.” Gilead Sciences, Inc. (NASDAQ:GILD) reminds us of this core trading principle right now, after breaking powerfully under a key support level with positive divergences, overruling any reversal signal to keep the persistent downtrend in motion.
NASDAQ:GILD February 9, 2017 10:52am

Biotech ETF Surges On Positive Trump Comments

donald trump
The iShares Nasdaq Biotechnology Index Fund (IBB) outperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a dollar basis, producing a +2.84% one-day return and outperforming the wider markets by a total of 2.85 percentage points.
NASDAQ:IBB January 31, 2017 5:51pm

BioShares Biotech Clinical Trials Fund, Up 5%, Is Today’s Top Performing ETF

The BioShares Biotechnology Clinical Trials Fund (BBC) outperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a +5.03% one-day return and outperforming the wider markets by a total of 5.04 percentage points.

Pfizer Provides Tepid Outlook As Q4 Results Miss Expectations

From Pfizer Inc. (NYSE:PFE) early Tuesday posted disappointing fourth quarter results and offered a tepid outlook, amid weakening demand for some of its key drugs.

Can Biotech ETFs Survive A Trump Presidency?

From Zacks: Biotech stocks have been under intense pressure for more than a year now with sector-specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario weighing on the sector.
NASDAQ:IBB January 28, 2017 9:37am

AbbVie Issues In-Line Outlook Following Mixed Q4 Earnings

From AbbVie Inc (NYSE:ABBV) early Friday posted mixed fourth quarter earnings results and issued a 2017 forecast that was in-line with Wall Street expectations.
NYSE:ABBV January 27, 2017 8:19am

Bristol-Myers Slashes Outlook As Q4 Profit Misses The Mark

From Bristol-Myers Squibb Co (NYSE:BMY) early Thursday posted mixed fourth quarter earnins reuslts and lowered its 2017 outlook, amid fears of regulators capping drug prices.
NYSE:BMY January 26, 2017 8:09am

Biogen Shares Down After Q4 Earnings, 2017 Weak Outlook

From Biogen Inc (NASDAQ:BIIB) early Thursday posted mixed fourth quarter earnings results and offered a tepid 2017 outlook that sent its shares plunging.

Recommended for You

Explore More from

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again! respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories